Hybridoma technology has greatly in speeding up antibody drug discovery process. However, hybridoma cell line has its own disadvantages, such as contamination, low yield and storage space limitation. Hybridoma sequencing can overcome these disadvantages and it can also prevent the lost hybridoma cell line. Your candidate antibody can always be manufactured via recombinant expression after sequencing with mammalian cells, such as HEK/CHO.
BioIntron can provide a quick and professional hybridoma sequencing to get monoclonal antibody sequence for our customers. BioIntron’s HTP rAb expression platform can also help our client to expression the candidate antibody in only 2 weeks after obtaining the sequence.